Allogeneic stem cell transplantation in therapy-related myelodysplasia after autologous transplantation for lymphoma: a retrospective study of the SFGM-TC. Biol Blood Marrow Transplant. 2019.
Autologous stem-cell collection following VTD or VRD induction therapy in multiple myeloma: a single-center experience. Bone Marrow Transplant. 2020.
Clinical and Economic Impact of Treated CMV Infection in Adult CMV-seropositive Patients after Allogeneic Hematopoietic Cell Transplantation. J Med Virol. 2020.
Comparative Outcomes of Myeloablative and Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Therapy-Related Acute Myeloid Leukemia with Prior Solid Tumor: a report from the ALWP of the EBMT. Am J Hematol. 2018.
Comparison of mycophenolate mofetil and calcineurin inhibitor versus calcineurin inhibitor-based graft-versus-host-disease prophylaxis for matched unrelated donor transplant in acute myeloid leukemia. A study from the ALWP of the EBMT. Bone Marrow Transplant. 2020.
Evaluation of infectious complications after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide following reduced-intensity and myeloablative conditioning: a study on behalf of the Francophone Society of Stem Cell. Bone Marrow Transplant. 2019.
FLT3 ligand plasma levels have no impact on outcomes after allotransplant in acute leukemia. Cytokine. 2019;120:85-87.
Grade 2 acute GVHD is a factor of good prognosis in patients receiving peripheral blood stem cells haplo-transplant with post-transplant cyclophosphamide. Acta Oncol. 2020:1-9.
HHV-6 reactivation before engraftment is strongly predictive of graft failure after double umbilical cord blood allogeneic stem cell transplantation in adults. Exp Hematol. 2014.
High CD3+ and CD34+ peripheral blood stem cell grafts content is associated with increased risk of graft-versus-host disease without beneficial effect on disease control after reduced-intensity conditioning allogeneic transplantation from matched unrelate. Oncotarget. 2016.
HLA mismatched donors in patients with myelodysplastic syndrome: an EBMT registry analysis. Biol Blood Marrow Transplant. 2018.
The impact of advanced patient age on mortality after allogeneic hematopoietic Cell Transplantation for Non-Hodgkin's Lymphoma: A retrospective study by the EBMT Lymphoma Working Party. Biol Blood Marrow Transplant. 2018.
Influence of donor type (sibling vs matched-unrelated donor vs haplo-identical donor) on outcomes after clofarabine-based reduced-intensity conditioning allograft for myeloid malignancies. Biol Blood Marrow Transplant. 2019.
Outcomes of advanced Hodgkin lymphoma after umbilical cord blood transplantation: a Eurocord and EBMT Lymphoma and Cellular Therapy & Immunobiology Working Party study. Biol Blood Marrow Transplant. 2018.
Outcomes of Cord Blood Transplantation Using Reduced Intensity Conditioning for Chronic Lymphocytic Leukemia: a Study on Behalf of Eurocord and Cord Blood Committee of Celular Therapy and Immunobiology Working Party(CTIWP), Chronic Malignancies Working Pa. Biol Blood Marrow Transplant. 2015.
Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study. J Clin Oncol. 2015.
Peripheral blood plasmacytoid dendritic cells at day 100 can predict outcome after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2015..
Post-transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-identical sibling donors: A retrospective analysis from the Acute Leukemia Working Party o. Cancer. 2020.
Results from a clofarabine-busulfan containing reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase II prospective CLORIC trial. Haematologica. 2014.
Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. Blood. 2015.
Sequential allogeneic hematopoietic stem cell transplantation for active refractory/relapsed myeloid malignancies: results of a reduced-intensity conditioning preceded by clofarabine and cytosine arabinoside, a retrospective study on behalf of the SFGM-TC. Ann Hematol. 2020.